Aptorum Group (Aptorum Group) Gross-Profit-to-Asset % : 0.06% (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Aptorum Group's annualized Gross Profit for the quarter that ended in Jun. 2023 was $0.01 Mil. Aptorum Group's average Total Assets over the quarter that ended in Jun. 2023 was $17.64 Mil. Therefore, Aptorum Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 0.06%.

Aptorum Group Gross-Profit-to-Asset % Historical Data

The historical data trend for Aptorum Group's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Gross-Profit-to-Asset % Chart

Aptorum Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.17

-0.75

-0.31

0.25

0.37

Aptorum Group Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial							0.04	0.55	-0.03	0.74	0.06

Competitive Comparison of Aptorum Group's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Aptorum Group's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptorum Group's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptorum Group's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Aptorum Group's Gross-Profit-to-Asset % falls into.

Aptorum Group Gross-Profit-to-Asset % Calculation

Aptorum Group's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	0.08	/	( (21.907	+	20.867)	/ 2 )
	=	0.08	/	21.387
	=	0.37 %

Aptorum Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	0.01	/	( (20.867	+	14.412)	/ 2 )
	=	0.01	/	17.6395
	=	0.06 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Aptorum Group Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptorum Group (Aptorum Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.aptorumgroup.com

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.